EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial)



Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial)



American Journal of Cardiology 91(1): 17-21



The role of platelet glycoprotein IIb/IIIa inhibitor therapy in patients with mild renal impairment is not well characterized. Our objective was to explore the associations of creatinine clearance (CrCl) with outcomes in a trial of eptifibatide therapy in patients who underwent percutaneous coronary intervention (PCI). We analyzed 48-hour and 30-day outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial. Patients were randomly assigned to placebo or eptifibatide as an adjunct to stent implantation (1,755 with CrCl gtoreq60 ml/min and 289 with CrCl <60 ml/min). CrCl was calculated using the Cockcroft and Gault formula, and the associations of CrCl with outcomes were evaluated using logistic regression models. Patients with CrCl <60 ml/min were more likely to be older, women, hypertensive, and have a history of coronary artery bypass surgery, stroke, or peripheral vascular disease. The interaction of eptifibatide with CrCl had borderline significance for the 30-day outcome (p=0.109). Treatment effect trended toward a greater magnitude in patients with lower CrCl (60 ml/min) (odds ratio 0.53, confidence interval 0.34 to 0.83) compared with those with higher CrCl (90 ml/min) (odds ratio 0.68, confidence interval 0.49 to 0.94). An accompanying increase in bleeding risk also was not apparent with lower CrCl. The treatment effect of eptifibatide is realized regardless of renal function and trends toward being greater in patients with mild renal impairment.

(PDF emailed within 0-6 h: $19.90)

Accession: 011590744

Download citation: RISBibTeXText

DOI: 10.1016/s0002-9149(02)02991-0



Related references

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). American Journal of Cardiology 91(1): 17-21, 2002

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356(9247): 2037-2044, 2001

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled study. Indian Heart Journal 53(3): 376-376, 2001

Eptifibatide in coronary stent implantation Long-term results of the ESPRIT trial. Circulation 104(17 Supplement): II 94, October 23, 2001

High-dose eptifibatide in elective coronary stent implantation Results of the ESPRIT trial. European Heart Journal 21(Abstract Supplement): 146, August-September, 2000

High-dose eptifibatide in coronary stent implantation 1 Year results of the ESPRIT trial. Journal of the American College of Cardiology 37(2 Supplement A): 76A, February, 2001

High-dose eptifibatide in coronary stent implantation 6 Month results of the ESPRIT trial. Circulation 102(18 Supplement): II 663, October 31, 2000

In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. American Journal of Cardiology 89(1): 61-64, 2002

Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting Results from the ESPRIT trial. Circulation 104(17 Supplement): II 386-II 387, October 23, 2001

Effect of Eptifibatide on coronary flow reserve following coronary stent implantation (An ESPRIT substudy). American Journal of Cardiology 87(11): 1293-1295, 2001

Treatment effect at different levels of creatinine clearance following eptifibatide in planned coronary stent implantation. Journal of the American College of Cardiology 37(2 Supplement A): 11A, February, 2001

Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheterization and Cardiovascular Interventions 70(1): 43-50, 2007

Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. American Journal of Cardiology 87(11): 1293-1295, 2001

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA (Journal of the American Medical Association) 285(19): 2468-2473, May 16, 2001